Dr. Reddys Laboratories Ltd.

Dr Reddy’s Lab is currently trading at Rs. 1845.00, up by 6.65 points or 0.36% from its previous closing of Rs. 1838.35 on the BSE.

The scrip opened at Rs. 1844.80 and has touched a high and low of Rs. 1846.95 and Rs. 1833.70 respectively. So far 1923 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 1850.00 on 06-Dec-2012 and a 52 week low of Rs. 1528.00 on 19-Jun-2012.

Last one week high and low of the scrip stood at Rs. 1850.00 and Rs. 1804.00 respectively. The current market cap of the company is Rs. 31,321 crore.

The promoters holding in the company stood at 25.56% while Institutions and Non-Institutions held 39.75% and 17.76% respectively.

Dr Reddy’s Laboratories, has introduced PamorelinÒ LA in India under an exclusive marketing and sales agreement with Debiopharm Group, Switzerland. The company will import this drug in bulk from Debio Recherche Pharmaceutique and made available primarily to urologists and oncologists across India. PamorelinÒ LA is used for the treatment of locally advanced or metastatic, hormone-dependent prostate cancer.

Dr Reddy's is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, bio-similars, differentiated formulations and NCEs